GNE Myopathy — encompassing Nonaka Myopathy, Hereditary Inclusion Body Myopathy (HIBM, OMIM #600737), and Distal Myopathy with Rimmed Vacuoles (DMRV), three clinical designations for the same autosomal recessive distal myopathy caused by biallelic pathogenic mutations in GNE (glucosamine [UDP-N-acetyl]-2-epimerase/N-acetylmannosamine kinase gene, chromosome 9p13.3) — arises from dysfunction of a bifunctional enzyme that catalyzes the first two rate-limiting steps of sialic acid biosynthesis: the epimerization of UDP-GlcNAc to ManNAc by the epimerase domain, and the phosphorylation of ManNAc to ManNAc-6-phosphate by the kinase domain; sialic acid — N-acetylneuraminic acid (Neu5Ac) — is the terminal sugar residue added to the complex carbohydrate chains of glycoproteins and glycolipids on virtually all mammalian cell surfaces, and in skeletal muscle it decorates the surface glycoproteins of the sarcolemma that are critical for membrane integrity, mechanosignaling, and structural organization; biallelic GNE mutations reduce total cellular sialic acid production capacity, causing progressive hyposialylation of muscle surface glycoproteins — α-dystroglycan, NCAM, neuropilin-2, and others — and a poorly understood downstream cascade of progressive muscle fiber degeneration that selectively affects specific muscle groups with a remarkably predictable anatomical pattern; the clinical hallmarks of GNE myopathy are distinct and diagnostically informative: adult onset typically in the 2nd or 3rd decade of life (range 15–50 years), a highly characteristic distal lower limb onset with tibialis anterior muscle weakness causing foot drop and a steppage gait as the presenting feature in the great majority of patients, progressive spread to involve other distal lower limb muscles (peroneal muscles, toe extensors), followed by distal upper limb involvement affecting wrist extensors and finger extensors, with the cardinal diagnostic hallmark of QUADRICEPS SPARING — the quadriceps femoris muscles are remarkably preserved until very late stages of the disease, often remaining at near-normal strength for decades while all surrounding lower limb muscles are severely affected; this selective quadriceps sparing is a near-pathognomonic feature of GNE myopathy that is virtually unique among the muscular dystrophies and distal myopathies, and its documentation is essential for both diagnosis and differentiation from inclusion body myositis (IBM), which has an overlapping rimmed vacuole biopsy appearance but affects quadriceps early and presents in older patients; muscle biopsy in GNE myopathy reveals myopathic changes with the defining pathological feature of rimmed vacuoles — autophagic vacuoles rimmed by granular material containing TDP-43 (TARDBP), p62/sequestosome-1, and ubiquitin inclusions — that link GNE myopathy to the broader class of rimmed vacuole myopathies sharing a protein aggregate pathology despite different genetic causes; cardiac involvement is generally not a feature of GNE myopathy (unlike desminopathy or other protein aggregate myopathies), and respiratory involvement is similarly uncommon until very late disease stages; serum creatine kinase is mildly to moderately elevated (typically 2–10 times the upper limit of normal, lower than the extreme elevations seen in some other muscular dystrophies); diagnosis is confirmed by identification of biallelic pathogenic GNE variants — a p.M743T (c.2228T>C) founder mutation in the kinase domain is present in the majority of affected Japanese patients, while Middle Eastern Jewish patients have a different founder mutation (p.M712T), and non-founder mutations are distributed throughout the gene in non-Japanese, non-Middle-Eastern populations; there is no approved disease-modifying therapy for GNE myopathy; sialic acid substrate replacement approaches — oral aceneuramic acid (Neu5Ac) and N-acetylmannosamine (ManNAc) — have been investigated in clinical trials with mixed results on functional endpoints, and the field continues to evaluate substrate supplementation, gene therapy, and other sialylation restoration strategies in a disease where natural history registry data from multiple international cohorts (including GNE Myopathy Disease Monitoring Program, GNEM-DMP) are accumulating to inform endpoint selection for future trials.
GNE myopathy technology platforms — covering the neuromuscular diagnostic platforms where young adults with progressive foot drop and steppage gait enter the diagnostic pathway, the longitudinal muscle function tracking platforms generating the distal-focused dynamometry, gait assessment, and functional capacity records that establish the natural history trajectory essential for trial eligibility and registry participation, the quadriceps surveillance platforms creating the serial measurements that document the selective sparing pattern essential to diagnosis and registry characterization, the gait analysis and orthotic management platforms coordinating ankle-foot orthosis prescription and review for the foot drop that defines the early functional disability, the hand and upper limb function assessment platforms tracking fine motor deterioration in wrist and finger extensors as the disease spreads from lower to upper limbs over years to decades, the physiotherapy coordination platforms scheduling compensatory strategies for a disease where progressive distal weakness requires adaptive equipment, orthotic management, and falls prevention rather than muscle-strengthening exercise, the falls risk assessment and prevention platforms recording the stumbling and tripping falls caused by foot drop in an ambulatory patient population where maintained ambulation over many years is the goal, the walking aid progression platforms tracking the long clinical course from unassisted ambulation through ankle-foot orthosis to walking aid use, the genetic documentation platforms recording biallelic GNE variants with founder mutation context for Japanese and Middle Eastern patients, the natural history registry coordination platforms managing participation in GNE myopathy registries and longitudinal cohort studies that are the infrastructure for future clinical trials, and the research trial eligibility platforms that match enrolled registry participants to emerging therapeutic trials — must maintain the availability and performance that sialic-acid-biology-informed care, quadriceps sparing documentation, gait management, registry participation, and trial eligibility tracking require. This guide explains why GNE myopathy care tech platforms require specialized monitoring, what to monitor, and how to build a monitoring strategy calibrated to the distal weakness pattern, quadriceps sparing hallmark, registry coordination needs, and trial landscape of GNE myopathy.
Why GNE Myopathy Tech Platforms Require Specialized Monitoring Attention
GNE myopathy presents unique platform dependencies arising from its distal-predominant weakness pattern, the diagnostic significance of quadriceps sparing documentation, the long ambulatory course requiring sustained orthotic and physiotherapy coordination, and the registry-dependent infrastructure for future clinical trials.
Quadriceps serial measurement platforms document the selective sparing pattern that is both diagnostic and registry-critical. The near-complete preservation of quadriceps strength in GNE myopathy while surrounding muscles are severely affected is a hallmark so specific that it functions as a diagnostic criterion and is a primary registry variable in international GNE myopathy natural history studies. Serial quadriceps dynamometry records create the longitudinal dataset documenting the duration and degree of quadriceps preservation that is requested by trial eligibility assessors and registry curators. Platform failures during quadriceps assessment sessions destroy the temporal documentation of this hallmark and compromise registry data completeness. Monitor during clinical hours.
Distal lower limb and foot drop management platforms coordinate the gait orthotic care that defines early functional management. Tibialis anterior weakness causing foot drop and steppage gait is the presenting feature in most GNE myopathy patients, and ankle-foot orthosis prescription, fitting, and gait re-evaluation form the core early management intervention that determines whether the patient maintains safe community ambulation or develops progressive falls from uncompensated foot drop. Platform failures interrupting orthotic prescription records, AFO fitting documentation, or post-orthotic gait re-evaluation records break the care chain for the intervention most consequential to early functional independence. Monitor during clinical hours.
Natural history registry coordination platforms are the trial eligibility infrastructure for a disease with no approved therapy. GNE myopathy clinical trial development depends on natural history registry data — longitudinal functional measurements, genetic documentation, and demographic records accumulated through platforms that manage registry enrollment, visit scheduling, data capture, and eligibility matching. A registry coordination platform that fails during a scheduled visit means that a patient's longitudinal data point is not recorded, their trial eligibility status is not updated, and the registry dataset that trial sponsors use to design and power future studies is incomplete. Monitor during clinical hours and registry visit windows.
Hand and upper limb function tracking platforms record the disease spread that signals advanced disease. The progression of GNE myopathy from distal lower limb weakness to distal upper limb involvement — wrist extensor and finger extensor weakness affecting grip, writing, typing, and self-care tasks — marks a clinically significant stage transition that triggers occupational therapy referrals, adaptive equipment prescription, and fine motor assistive technology. Platform failures during hand function assessments prevent the documentation of this spread that determines the patient's care stage and functional support needs. Monitor during clinical hours.
Gait assessment and falls risk platforms protect ambulatory patients from preventable injury. GNE myopathy patients remain ambulatory for many years or decades, and the progressive foot drop that characterizes the early and middle disease stages creates a sustained and increasing falls risk from toe-catch stumbling. Falls risk documentation, home assessment records, and referral coordination for falls prevention are active care platform functions throughout the long ambulatory phase. Monitor during clinical hours.
What to Monitor on a GNE Myopathy Care Tech Platform
Distal Muscle Strength and Functional Assessment Records
Monitor dynamometry assessment records at each clinic visit documenting tibialis anterior strength (ankle dorsiflexion — the primary and earliest affected muscle; the most important serial measurement in GNE myopathy), peroneal muscle strength (ankle eversion and foot eversion), extensor digitorum longus strength (toe extension), gastrocnemius and soleus strength (ankle plantar flexion — relatively preserved compared to dorsiflexors), wrist extensor strength (extensor carpi radialis and ulnaris — documents upper limb spread), wrist flexor strength, finger extensor strength (extensor digitorum communis — documenting progression to fine motor difficulty), grip strength dynamometry, pinch strength, and proximal muscle strength documentation (hip flexors, hip extensors, knee extensors — with particular attention to quadriceps strength; document each as percentage of predicted normal and record trajectory); foot dorsiflexion strength asymmetry documentation (early GNE myopathy may show asymmetric onset — document each limb separately); handheld dynamometry records expressed in Newtons or kilograms with standardized positions for inter-visit comparability; manual muscle testing records using MRC scale; GFAQ (Generalized Functional Assessment Questionnaire) or equivalent structured functional rating; 6-minute walk test records with comparison against prior results and GNE myopathy natural history normative values; timed motor function tests including 10-meter walk time, timed up-and-go, 4-stair climb time; and step count monitoring records for ambulatory patients using wearable activity monitors where collected as research outcome. Alert on assessment platform failures during scheduled clinic visits.
Quadriceps Surveillance and Selective Sparing Documentation
Monitor serial quadriceps strength measurement records at every clinical visit — this is the most important single dataset for GNE myopathy diagnosis confirmation and registry documentation; document knee extensor strength by handheld dynamometry and manual muscle testing at each visit, express as percentage of age-sex predicted normal, and calculate quadriceps-to-tibialis-anterior strength ratio (the preserved quadriceps to severely affected tibialis anterior ratio is the mathematical expression of the selective sparing hallmark); quadriceps bulk assessment records from clinical examination and where available from MRI muscle imaging (T1-weighted and fat fraction estimates — documenting preserved quadriceps signal intensity while surrounding muscles show fatty infiltration); MRI muscle imaging records for muscles of the thigh and lower leg when available (pattern recognition — preserved quadriceps signal with early fatty infiltration of tibialis anterior, gastrocnemius, and other distal muscles is the pathognomonic GNE myopathy MRI pattern); documentation of any quadriceps weakness onset (a significant clinical event indicating late or advanced disease — trigger for care escalation review); and registry data submission confirmation records for quadriceps measurements (GNE myopathy natural history registries specifically request serial quadriceps data). Alert on quadriceps platform failures during clinical sessions.
Gait Assessment and Ankle-Foot Orthosis Management
Monitor gait assessment records documenting foot drop severity (heel strike pattern, toe clearance during swing phase, steppage gait pattern, foot slap), gait velocity measurement, step length and cadence documentation, video gait analysis records where available, shoe wear pattern assessment (increased lateral toe wear consistent with foot drop), formal gait laboratory records where collected; ankle-foot orthosis prescription records (timing of first AFO prescription, AFO type — solid vs. articulated, carbon fiber dynamic vs. polypropylene), AFO fitting records, gait re-evaluation on AFO documenting improvement in foot clearance and gait velocity, AFO adherence records (hours per day worn, compliance barriers), orthotist communication records, AFO review and replacement records; walking aid progression records tracking the transition from unassisted ambulation through AFO use to Lofstrand crutch or walking frame; and community ambulation distance and environment documentation (can patient manage stairs, uneven surfaces, community distances on AFO). Monitor during clinical hours.
Falls Risk Assessment and Prevention
Monitor falls risk screening records at each clinic visit using a validated tool (Falls Risk Assessment Tool or equivalent), prospective falls diary records (monthly patient-reported falls log — total falls per month, circumstances, injury sustained, call for help required), near-miss stumbling event records documenting frequency and context, home hazard assessment records from occupational therapy visits (removal of loose rugs, installation of handrails, bathroom grab rails, stair lift assessment in multilevel homes), falls prevention referral records, falls-related injury records (fractures, soft tissue injuries — with mechanism documentation), emergency department visit records from falls, footwear assessment records (rocker-sole shoes to assist toe clearance; avoidance of slip-on footwear without heel support), night-time safety records (lighting assessment — foot drop falls at night in unfamiliar environments), and walking aid prescription timing records. Alert on falls risk platform failures during clinical contact windows.
Hand Function and Fine Motor Assessment
Monitor hand function assessment records at each clinic visit including grip dynamometry (Jamar or equivalent — bilateral), lateral and tripod pinch strength, writing assessment records (timed writing test — documenting speed and legibility decline), typing speed and accuracy records where collected, activities of daily living hand function records (fastening buttons, cutlery use, jar opening, key turning — self-reported and observational), fine motor test records (nine-hole peg test, purdue pegboard where available), occupational therapy hand assessment records, adaptive equipment prescription records (pen grips, built-up cutlery, jar openers, button hooks, key turners), hand orthosis records (wrist extension splints, resting hand splints — for wrist and finger extensor weakness), and work accommodation records for patients with occupationally demanding hand function requirements. Monitor during clinical hours.
Physiotherapy and Orthopedic Coordination
Monitor physiotherapy scheduling and attendance records for GNE myopathy-specific programs, home exercise program documentation (stretching for calf and Achilles tendon contractures — shortened heel cords develop secondary to tibialis anterior weakness and disuse of dorsiflexion; passive range of motion exercises for ankle, foot, and wrist; low-intensity strengthening within preserved muscle groups), aquatic physiotherapy records (hydrotherapy — buoyancy-assisted gait training, range of motion in warm water), Achilles tendon contracture management records (stretching, serial casting, orthopedic review for surgical lengthening when contracture prevents AFO fitting), ankle contracture measurement records (passive ankle dorsiflexion angle — documents contracture development), upper limb physiotherapy records (forearm, wrist, and finger extensor stretching; functional upper limb exercise programs as distal upper limb weakness develops), physiotherapy outcome measurement records, and multidisciplinary team meeting records. Monitor during clinical hours.
Genetic Documentation and Registry Coordination
Monitor GNE biallelic pathogenic variant documentation records — both alleles with HGVS nomenclature, ACMG/AMP classification, method of detection (NGS panel, exome sequencing, Sanger confirmation), founder mutation context documentation (Japanese ancestry: p.M743T [c.2228T>C] kinase domain founder mutation frequency; Middle Eastern Jewish ancestry: p.M712T [c.2135C>T] alternate founder mutation; non-founder populations — variant distribution across both epimerase and kinase domains); natural history registry enrollment records (GNE Myopathy Disease Monitoring Program, GNEM-DMP, institutional registries — enrollment date, data submission schedule, visit windows); registry visit scheduling and completion records; trial eligibility database records (eligibility criteria match status, trial enrollment status, past trial participation); genetic counseling records (autosomal recessive inheritance — sibling testing, reproductive counseling, offspring carrier status when applicable); and inter-laboratory variant report reconciliation records for patients with multi-laboratory testing histories. Monitor registry platform availability during visit windows.
Authentication and Clinical Access
Monitor authentication at 1-minute intervals, 24/7. GNE myopathy multidisciplinary care teams spanning neuromuscular specialists, physiotherapists coordinating orthotic management and Achilles contracture prevention, occupational therapists managing hand function adaptations, orthotists for AFO review, genetic counselors coordinating registry enrollment and family testing, trial coordinators managing longitudinal natural history data, and research coordinators require concurrent platform access during longitudinal assessment visits where functional trajectory, quadriceps sparing documentation, registry data submission, and trial eligibility assessment are reviewed concurrently.
SSL Certificates
Monitor SSL certificate expiry across genetic variant documentation platforms, registry coordination portals, quadriceps surveillance record systems, gait analysis and AFO management platforms, muscle function tracking applications, hand function assessment platforms, falls risk documentation systems, physiotherapy coordination portals, trial eligibility matching systems, and patient communication portals. Certificate errors in registry submission pathways or trial eligibility systems carry the highest urgency given the research infrastructure implications for a disease with no approved therapy.
HIPAA and GNE Myopathy Patient Privacy Considerations
GNE myopathy technology platforms handle PHI categories including GNE biallelic pathogenic variant records with GINA protections and autosomal recessive inheritance implications for siblings and offspring, founder mutation status records (Japanese p.M743T; Middle Eastern p.M712T) with population ancestry implications, longitudinal muscle function datasets spanning decades of progressive disease documentation used in both clinical management and natural history research, natural history registry records with dual clinical and research purpose, trial enrollment and participation records, quadriceps strength serial measurement datasets with diagnostic significance, gait analysis records, and falls injury records with potential occupational and insurance implications. HIPAA Security Rule and GINA protections apply across all platform components, with particular attention to genetic variant records, registry participation records, and trial eligibility data.
Alerting Strategy for GNE Myopathy Tech Platforms
Immediate 24/7 alerting: Authentication.
Immediate clinical-hours alerting: Registry visit window alerts (scheduled natural history data submission windows with hard deadlines); trial eligibility expiration alerts (time-limited enrollment windows for open trials); falls injury alert records requiring urgent care coordination.
Sustained-failure alerting (10–15 minutes): Distal muscle strength and functional assessment tracking; quadriceps surveillance and selective sparing documentation; gait assessment and AFO management platforms; hand function and fine motor assessment platforms; falls risk documentation; physiotherapy coordination; registry enrollment and data submission platforms; genetic documentation platforms; patient portal and family communication systems.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms GNE myopathy platform availability from the geographies where neuromuscular disease centers with GNE myopathy expertise, Japanese and Middle Eastern Jewish population neuromuscular programs, natural history registry coordination sites, and emerging therapeutic trial centers serve young adults with a progressive distal myopathy whose care and research participation depend on sustained platform availability across a disease course spanning decades.
Status Page for GNE Myopathy Care Team Communication
A real-time status page gives neuromuscular specialists scheduling quadriceps surveillance and distal muscle assessment visits, physiotherapists coordinating Achilles contracture prevention and home exercise programs, orthotists reviewing AFO fit and function, occupational therapists managing hand function and adaptive equipment, genetic counselors coordinating registry enrollment and family testing, registry coordinators managing natural history data submission, trial coordinators tracking eligibility status, and families navigating a progressive rare distal myopathy immediate platform visibility without requiring IT support contact.
Include the status page URL in neuromuscular clinic emergency procedures, registry coordinator communication protocols, and trial site emergency contacts.
Vigilmon Setup for GNE Myopathy Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Registry visit window alerts | 1 min | Slack + PagerDuty (clinical hours) | | Trial eligibility expiration alerts | 1 min | Slack + PagerDuty (clinical hours) | | Quadriceps surveillance and sparing documentation | 2 min | Slack (clinical hours) | | Tibialis anterior and distal dynamometry tracking | 2 min | Slack (clinical hours) | | Gait assessment and AFO management | 2 min | Slack (clinical hours) | | Hand function and fine motor assessment | 2 min | Slack (clinical hours) | | Falls risk screening and prevention | 2 min | Slack (clinical hours) | | 6-minute walk test and timed motor tests | 2 min | Slack (clinical hours) | | Physiotherapy scheduling and attendance | 2 min | Slack (clinical hours) | | Achilles contracture management records | 2 min | Slack (clinical hours) | | Natural history registry coordination | 2 min | Slack (clinical hours) | | Genetic documentation (GNE biallelic variants) | 2 min | Slack (lab hours) | | Genetic counseling and family testing coordination | 2 min | Slack (clinical hours) | | Patient portal / family communication | 2 min | Slack (extended hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 PagerDuty alerting
- Configure registry visit window alerts with immediate clinical-hours alerting
- Add trial eligibility expiration alerts with immediate alerting
- Configure quadriceps surveillance platforms with sustained-failure alerting
- Add tibialis anterior and distal dynamometry tracking
- Configure gait assessment and AFO management platforms
- Add hand function and fine motor assessment platforms
- Configure falls risk screening and prevention platforms
- Add 6-minute walk test and timed motor function records
- Configure physiotherapy coordination platforms
- Add Achilles contracture management and orthopedic coordination records
- Configure natural history registry coordination platforms
- Add genetic documentation and counseling platforms with laboratory-hours alerting
- Enable SSL certificate monitoring across all neuromuscular, registry, and trial platforms
- Add the status page URL to neuromuscular clinic emergency procedures and registry coordinator protocols
Conclusion
GNE myopathy technology platforms operate in the context of a rare distal myopathy defined by a sialic acid biosynthesis defect whose clinical expression — progressive foot drop in young adults with the diagnostic hallmark of quadriceps sparing lasting for decades — creates management-critical platform dependencies centered on gait documentation, orthotic coordination, quadriceps surveillance, and registry participation that are specific to GNE myopathy's biology and trial development landscape; the quadriceps surveillance platform that fails during a longitudinal assessment visit for a 28-year-old woman with biallelic GNE p.M743T mutations means that the serial quadriceps dynamometry record — knee extensor strength 82% predicted bilaterally while tibialis anterior strength is 28% predicted, maintaining the 3:1 quadriceps-to-anterior-tibialis ratio that documents the pathognomonic sparing — is not entered, the registry data submission for this visit is incomplete, the natural history curator flags the missing data point, and the trial eligibility assessor reviewing her record for an emerging sialic acid substrate supplementation trial cannot confirm her eligibility from incomplete longitudinal data; a gait assessment and AFO management platform that fails during the orthopedic coordination appointment for a 33-year-old man with GNE myopathy and progressive foot drop means that the AFO fitting record, gait re-evaluation on ankle-foot orthosis, and orthotist communication note documenting the 0.4 m/s improvement in gait velocity with articulated AFO use are not created, the next clinic visit cannot compare gait velocity on and off orthosis, and the decision about Achilles tendon lengthening — which would be informed by the record of AFO-dependent gait improvement — is made without the platform-dependent documentation that should support it; a falls risk documentation platform that fails during the quarterly falls review for a 41-year-old woman with GNE myopathy and bilateral foot drop means that her reported four stumbling falls in the preceding three months — two resulting in knee bruising, one in a wrist contusion — are not recorded, the home hazard assessment referral is not generated, the occupational therapy visit to remove the loose runner rug from her kitchen corridor and install a handrail on her front step is not triggered, and the fifth stumbling fall the following month fractures her distal radius and restricts her upper limb function for eight weeks in a patient whose finger extensor weakness was already limiting keyboard use at work; and a natural history registry coordination platform that fails during the annual registry data submission window for a GNE myopathy center means that the longitudinal functional records for twelve enrolled patients — tibialis anterior dynamometry, quadriceps surveillance, 6-minute walk test distances, gait velocity measures, and hand function assessments — are not submitted within the registry's data acceptance window, the twelve patients' records are marked as incomplete for the year, and the registry dataset available to trial sponsors designing the next ManNAc replacement study is smaller and less statistically powered by exactly those twelve longitudinal trajectories. These failures occur in a disease where no approved therapy exists, where the registry and natural history infrastructure are the foundation on which future trials will be designed, and where the platform reliability that sustains registry participation, quadriceps documentation, and gait management is the reliability on which clinical trial development for GNE myopathy depends.
Uptime monitoring gives GNE myopathy care tech teams the detection capability to identify platform failures within seconds, activate clinical downtime procedures that protect quadriceps surveillance records, registry coordination, gait assessment, and functional assessment data during outages, and demonstrate to neuromuscular disease centers with GNE myopathy expertise, natural history registry programs, trial sites evaluating sialic acid substrate therapies, and young adults with a progressive distal myopathy and a diagnostic hallmark worth protecting that platform reliability matches the precision and sustained longitudinal commitment that GNE myopathy management and research participation demand.
Start monitoring your GNE myopathy care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #GNEMyopathy #NonakaMyopathy #HIBM #DMRV #GNE #sialicAcid #distalMyopathy #quadricepsSparing #footDrop #rimmedVacuoles #TDP43 #muscleFunction #dynamometry #gaitAnalysis #AFO #naturalHistoryRegistry #HIPAA #healthtech #digitalhealth #uptime #sre